Enzon Pharmaceuticals, Inc. (ENZN)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
Feb 5, 2026, 9:30 AM EST
Enzon Pharmaceuticals Revenue
In the year 2024, Enzon Pharmaceuticals had annual revenue of $26.00K.
Revenue
26.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
5.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 26.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 26.00K | -675.00K | -96.29% |
| Dec 31, 2021 | 701.00K | 649.00K | 1,248.08% |
| Dec 31, 2020 | 52.00K | -155.00K | -74.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEnzon Pharmaceuticals News
- 6 days ago - Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger - GlobeNewsWire
- 3 months ago - Enzon and Viskase Announce Amendment to Merger Agreement - GlobeNewsWire
- 8 months ago - Enzon and Viskase Enter into Merger Agreement - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Announces Results of Rights Offering - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Announces Key Dates for Rights Offering - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting - GlobeNewsWire
- 5 years ago - Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders - GlobeNewsWire